MAY 26, 2020 1:39 PM PDT

Everyone Can Produce Antibodies Against COVID-19

WRITTEN BY: Annie Lennon

Researchers at Rockefeller University in New York have found that most people exposed to COVID-19, and who experience symptoms, can develop antibodies capable of blocking the virus. Their findings offer hope for the success of a potential vaccine, and research avenues for more drugs to combat it. 

Since April 1st, a team of researchers including immunologists, medical scientists, and virologists, has been collecting blood samples from people who have recovered from COVID-19. In total, they collected samples from 149 people over five weeks. Each participant experienced symptoms for an average of 12 days and had their first symptoms an average of 39 days before donating their blood. 

To test their antibodies, The researchers mixed their blood with a pseudo-COVID-19 virus in lab conditions. They then measured how well the mixture was then able to infect human cells in a petri dish. 

Although most of the samples had a poor to modest antibody response, closer inspection revealed that the problem was more to do with how many antibodies were present- as opposed to whether they were effective. Moreover, the researchers noted that those whose blood had antibodies below detectable levels might have been able to resolve the infection so quickly that the antibodies were not needed to be produced. 

"This suggests just about everybody can do this, which is very good news for vaccines," says Michel C. Nussenzweig, head of the Laboratory of Molecular Immunology at Rockefeller, and lead author of the study. "It means if you were able to create a vaccine that elicits these particular antibodies, then the vaccine is likely to be effective and work for a lot of people."

The researchers were also able to identify three distinct antibodies with a high potency against the virus. They are thus working on developing these antibodies into drugs both to treat and prevent COVID-19. 

 

Sources: bioRxiv, Medical Xpress

 

About the Author
  • Science writer with keen interests in technology and behavioral biology. Her current focus is on the interplay between these fields to create meaningful interactions, applications and environments.
You May Also Like
MAY 14, 2020
Cancer
New hope for immunotherapy for pediatric brain cancer
MAY 14, 2020
New hope for immunotherapy for pediatric brain cancer
Pediatric brain cancer is an especially tough pill to swallow. While one in four children does not survive medulloblasto ...
MAY 22, 2020
Drug Discovery & Development
Evaluating a Popular Diabetic Drug
MAY 22, 2020
Evaluating a Popular Diabetic Drug
A study by researchers at UT Southwestern study shows that a previous drug for Type 2 diabetes may be effective when pai ...
JUN 13, 2020
Neuroscience
High Doses of Ketamine Can Switch Off the Brain
JUN 13, 2020
High Doses of Ketamine Can Switch Off the Brain
Researchers from the University of Cambridge, England, have found that high doses of ketamine temporarily switch off the ...
JUN 13, 2020
Cannabis Sciences
CBD Kills Brain Cancer Cells in Petri Dish
JUN 13, 2020
CBD Kills Brain Cancer Cells in Petri Dish
Cannabis products are not only popular for their psychoactive effects. An increasing number of companies and researchers ...
JUL 01, 2020
Cancer
The MicroRNA That Can Regulate Tumor Vascularization in Liver Cancer
JUL 01, 2020
The MicroRNA That Can Regulate Tumor Vascularization in Liver Cancer
Angiogenesis is the vascularization, or generation of blood vessels, of a part of the body. It is a normal function of h ...
JUL 15, 2020
Cancer
Traditional Medicine Reveals a New Anti-Cancer Drug
JUL 15, 2020
Traditional Medicine Reveals a New Anti-Cancer Drug
The art of traditional eastern medicine dates back thousands of years. It uses many unproven remedies, and many consider ...
Loading Comments...